EMA Authorised: Zyprexa (olanzapine) — CHEPLAPHARM Registration GmbH

View source ↗

Summary

The EMA authorised Zyprexa (olanzapine) for schizophrenia and bipolar disorder under CHEPLAPHARM Registration GmbH as the marketing authorisation holder, decisi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Zyprexa (olanzapine)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: CHEPLAPHARM Registration GmbH. Decision date: 26/02/2026